CNS Pharmaceuticals, Inc. (CNSP)

US — Healthcare Sector
Peers: ZVSA  EFTR  VECT  AVRO  IMMX  NAVB  SONN  CWBR  OCEA  ENVB  ELEV  HEPA 

Automate Your Wheel Strategy on CNSP

With Tiblio's Option Bot, you can configure your own wheel strategy including CNSP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CNSP
  • Rev/Share 0.0012
  • Book/Share 4.0233
  • PB 0.256
  • Debt/Equity 0.0192
  • CurrentRatio 4.9374
  • ROIC -1.4037

 

  • MktCap 5625809.0
  • FreeCF/Share -6.2962
  • PFCF -0.3277
  • PE -0.1799
  • Debt/Assets 0.0153
  • DivYield 0
  • ROE -3.8541

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
CNSP
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral

Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / May 16, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "Our company remains focused as tightly as ever …

Read More
image for news CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CNSP
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral

HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of its "reasonable best efforts" public offering with a single healthcare focused institutional investor for the purchase and sale of 3,952,570 shares of common stock of the Company (the "Common Stock) (or common stock equivalents in lieu thereof), at a purchase price of $1.265 per share of Common Stock. The Company further agreed to issue to …

Read More
image for news CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
CNSP
Published: March 25, 2025 by: Accesswire
Sentiment: Neutral

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity.

Read More
image for news CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
CNSP
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral

Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025 at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland. In addition to the presentation, management will be available to participate in one-on-one …

Read More
image for news CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
CNSP
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral

On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, John Climaco, Chief Executive Officer of CNS Pharmaceuticals, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.

Read More
image for news CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

About CNS Pharmaceuticals, Inc. (CNSP)

  • IPO Date 2019-11-08
  • Website https://www.cnspharma.com
  • Industry Biotechnology
  • CEO Mr. John Michael Climaco Esq., J.D.
  • Employees 4

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.